Published in Clin J Am Soc Nephrol on September 15, 2011
Novel immunosuppressive agents in kidney transplantation. World J Transplant (2013) 0.96
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biologics (2012) 0.83
CD28 family and chronic rejection: "to belatacept...And beyond!". J Transplant (2012) 0.82
Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation. Nephrol Dial Transplant (2013) 0.78
Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy. Int J Nephrol Renovasc Dis (2016) 0.75
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice. Front Immunol (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol (2008) 2.59
Long-term survival in renal transplant recipients with graft function. Kidney Int (2000) 2.38
Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol (2003) 1.77
Cardiovascular toxicities of immunosuppressive agents. Am J Transplant (2002) 1.71
Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol (2000) 1.60
Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant (2008) 1.13
Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol (2002) 1.13
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant (2001) 1.08
Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation (1997) 1.07
Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int (2008) 1.01
Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transplant (2010) 0.90
Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant (2005) 0.89
Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation (2009) 0.88
Multivariate analysis of factors affecting patient and graft survival after renal transplant. Transplant Proc (2005) 0.88
Predictors of new onset diabetes after renal transplantation. Clin Transplant (2007) 0.88
Impact of diabetes mellitus on kidney transplant recipients in Spain. Nephrol Dial Transplant (2004) 0.83
Renal transplantation for type II diabetic patients compared with type I diabetic patients and patients over 50 years old: a single-center experience. Clin Transplant (2000) 0.79
Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res (2004) 5.40
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant (2003) 2.21
In-vivo interaction of nitric oxide and endothelin. J Hypertens (2004) 2.20
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int (2007) 2.03
Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation (2006) 1.81
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Clinical considerations for the development of biosimilars in oncology. MAbs (2015) 1.71
Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int (2005) 1.70
Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis (2010) 1.65
Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int (2002) 1.63
Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma. PLoS Pathog (2008) 1.60
Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis (2011) 1.53
Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens (2004) 1.51
Myosin IIb is unconventionally conventional. J Biol Chem (2003) 1.45
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Noncomposite simultaneous liver and intestinal transplantation. Transplantation (2003) 1.43
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant (2004) 1.43
[Prevalence of posttransplant hypertension in pediatric kidney transplant recipients: effect on long term allograft survival]. Rev Invest Clin (2011) 1.40
Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care (2005) 1.39
Characteristics of diabetes after pediatric liver transplant. Pediatr Transplant (2012) 1.39
[Document of Aguascalientes. Exhibition of reasons. First Transplantation Bioethics Forum. Latin American and Caribbean Transplantation Society]. Rev Invest Clin (2011) 1.38
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37
Docking and rolling, a model of how the mitotic motor Eg5 works. J Biol Chem (2005) 1.30
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
Switching of troponin I: Ca(2+) and myosin-induced activation of heart muscle. J Mol Biol (2004) 1.25
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
Measuring kinesin's first step. J Biol Chem (2002) 1.23
Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant (2005) 1.22
Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr Transplant (2013) 1.21
Structural kinetics of cardiac troponin C mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin complexes. J Biol Chem (2007) 1.20
DEC-205/CD205+ dendritic cells are abundant in the white pulp of the human spleen, including the border region between the red and white pulp. Immunology (2007) 1.19
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
Geographic disparity: the dilemma of lower socioeconomic status, multiple listing, and death on the liver transplant waiting list. Clin Transplant (2014) 1.14
Ca2+-induced conformational transition in the inhibitory and regulatory regions of cardiac troponin I. J Biol Chem (2003) 1.14
Proteomic analysis of proteins involved in spermiogenesis in mouse. J Proteome Res (2010) 1.13
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation (2011) 1.12
MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology (2009) 1.11
Effects of PKA phosphorylation of cardiac troponin I and strong crossbridge on conformational transitions of the N-domain of cardiac troponin C in regulated thin filaments. Biochemistry (2007) 1.11
Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit (2009) 1.11
Long-term outcomes after acute kidney injury. Crit Care Med (2008) 1.09
Novel strategies in immunosuppression: issues in perspective. Transplantation (2011) 1.09
miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur J Cancer (2011) 1.08
An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation (2010) 1.08
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol (2005) 1.06
Nucleic acid sequence-based amplification methods to detect avian influenza virus. Biochem Biophys Res Commun (2004) 1.06
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
Assessment of core capacities for the International Health Regulations (IHR[2005])--Uganda, 2009. BMC Public Health (2010) 1.05
Kinetics of conformational transitions in cardiac troponin induced by Ca2+ dissociation determined by Förster resonance energy transfer. J Biol Chem (2003) 1.04
A pathway of structural changes produced by monastrol binding to Eg5. J Biol Chem (2006) 1.04
Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology (2002) 1.04
A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A (2009) 1.04
Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett (2005) 1.02
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol (2010) 1.01
A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant (2005) 1.00
Incentives for organ donation: proposed standards for an internationally acceptable system. Am J Transplant (2011) 0.99
Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg (2014) 0.99
Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int (2008) 0.98
Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation (2009) 0.98
Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol (2007) 0.97
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation (2010) 0.97
Belatacept. Nat Rev Drug Discov (2011) 0.96
Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant (2004) 0.96
The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation (2009) 0.95
Structural transition of the inhibitory region of troponin I within the regulated cardiac thin filament. Arch Biochem Biophys (2006) 0.95
The ATPase cycle of the mitotic motor CENP-E. J Biol Chem (2009) 0.95
Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO-1-stained islets. Transplantation (2005) 0.94
Liver transplantation in children weighing 5 kg or less: analysis of the UNOS database. Pediatr Transplant (2011) 0.94
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J (2007) 0.93
Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol. Mol Cell Biochem (2013) 0.93
Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int (2012) 0.93
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int (2012) 0.92
Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation (2012) 0.92
Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation (2006) 0.92
Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation (2005) 0.92
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 0.92
Ionic liquid-bonded polysiloxane as stationary phase for capillary gas chromatography. J Sep Sci (2010) 0.91
Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation (2002) 0.89
Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant (2005) 0.89
Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost (2002) 0.89
FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant (2004) 0.89
Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant (2011) 0.88
Fulminant hepatic failure attributed to ackee fruit ingestion in a patient with sickle cell trait. Case Rep Transplant (2012) 0.87
High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant (2003) 0.87
Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant (2005) 0.87
Serotype and VP1 gene sequence of a foot-and-mouth disease virus from Hong Kong (2002). Biochem Biophys Res Commun (2003) 0.87
Medication level variability index predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl (2014) 0.87
Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag (2011) 0.87
Intrarenal cytokine and chemokine gene expression and kidney graft outcome. Kidney Blood Press Res (2007) 0.86
Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation (2005) 0.86
Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl (2010) 0.85
CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation (2003) 0.85